The changes occurring at the luminal surface of endothelial cells in diabetes and their relevance to endothelial dysfunction are poorly characterized in vivo. In this study, we developed an integrated strategy to discover cell surface proteins associated with diabetes and to test their role in endothelial dysfunction. First, a peptide phage display library was screened over the endothelial surface of the intact aorta or in retinal endothelial cells from diabetic and control rats. Then, we purified profilin-1 as a binding partner for one of the diabetic aorta-specific phage. Profilin was increased in the aortic endothelium of human diabetic individuals and streptozotocin-diabetic rats. Furthermore, overexpressing profilin in rat aortic endothelial cells triggered 3 indicators of endothelial dysfunction: increased apoptosis, elevated expression of ICAM-1, and decreased phosphorylation of the vasodilator-stimulated phosphoprotein, a marker for nitric oxide signaling. The changes in ICAM-1 and vasodilator-stimulated phosphoprotein were recapitulated in the diabetic aorta in vivo. LDL and oxysterols elevated profilin in cultured aortic endothelial cells. Interference with the de novo synthesis of profilin abrogated the LDLmediated increase in ICAM-1 expression. Finally, profilin expression was markedly elevated in atherosclerotic plaques. These data indicate that profilin contributes to endothelial dysfunction in a pathway that is downstream of LDL.
ascular abnormalities are a prevalent complication of both type 1 and type 2 diabetes (1−3), and cardiovascular events such as coronary artery disease and stroke are two-to four-fold more frequent in diabetic patients (4, 5) . In type 2 diabetes, factors such as hypertension (6) and dyslipidemia may contribute in concert with hyperglycemia to the etiology of macrovascular disease.
Endothelial dysfunction underlies and precedes the structural alterations of diabetic vascular disease (7, 8) , but its molecular bases are not fully clarified in vivo. Notably, it is not clear whether diabetes affects the repertoire of molecules presented on the luminal surface of endothelial cells (EC), either quantitatively (protein, lipid levels) or qualitatively (e.g., glycosylation). Changes at the luminal surface of EC might contribute to manifestations observed in diabetic individuals such as increased microthrombosis (9) , and accelerated atherosclerosis (4) . Using peptide phage display library, we developed an integrated strategy to V identify surface targets differentially expressed on the diabetic endothelium and test their function in diabetic vascular dysfunction. In vivo phage display library has been successfully used to characterize the molecular heterogeneity of EC surface in different organs (10, 11) and in cancer (12) . We have screened a peptide phage display library in the intact aorta and retinal EC of streptozotocin (STZ)-diabetic rats and identified diabetic-specific peptides for both tissues. Using a novel filter retention assay, we purified profilin-1 as a binding partner for one of the diabetic aorta-specific clone and began to test its role in EC dysfunction.
Profilin is a ubiquitous protein characterized for the ability to sequester actin monomers (13) , and accelerate actin filament turnover (14) . Also, profilin has been found to modulate EC migration and adhesion by contributing to the formation of focal contacts (15) . In addition, profilin interacts with signaling molecules including vasodilator-stimulated phosphoprotein (VASP) (16) , a validated marker for the activity of the Nitric Oxide (NO)/cGK pathway in vascular tissues (17, 18) . Profilin-1 mRNA is increased in mesangial cells exposed to the diabetic milieu (19) and in HUVEC treated with homocysteine under laminar flow conditions (20) . Finally, profilin protein is released in the extracellular space in experimental glomerulonephritis (21) .
Here we show that profilin levels are significantly increased in the aortic endothelium of diabetic individuals and STZ rats. Moreover, profilin overexpression in rat aortic EC (RAEC) triggered three indicators of endothelial dysfunction: intracellular adhesion molecule-1 (ICAM-1) upregulation, increased cell death by apoptosis and decreased VASP phosphorylation (hereafter indicated as phospho-VASP). The changes in ICAM-1 and phospho-VASP were recapitulated in the diabetic aorta in vivo. LDL/oxysterols, but not high glucose, was able to elevate profilin levels and interference with profilin de novo synthesis prevented ICAM-1 up-regulation in LDLtreated RAEC. Finally, profilin expression was markedly increased in the atherosclerotic plaque when compared with the adjacent tissue. These data suggest an unsuspected function for profilin as a mediator of endothelial dysfunction in a pathway downstream of LDL.
METHODS

Animals and organ isolation
Sprague-Dawley male rats were made diabetic with streptozotocin (55 mg/kg body weight i.v.), and insulin was given as needed (22) to achieve slow weight gain while maintaining hyperglycemia and glycosuria. Animals were euthanized after 5 months duration of diabetes, together with age-and sex-matched control rats. Glycohemoglobin was measured (Glyc-Affin; Pierce, Rockford, IL, USA) to assess the degree of hyperglycemia (17±1.9% in diabetic vs. 4.5±0.5% in control rats; P < 0.0001). Organs (aorta, retina, and the kidney) were isolated from rats anesthetized with ketamine/xylazine (70mg/kg and 9mg/kg body weight, respectively, i.m.), and perfused with prewarmed PBS through the left ventricle using a catheter connected to a peristaltic pump (4 min, ~100mmHg). The thoracic aorta was harvested, carefully freed of periadventitial fat, dissected longitudinally and placed on a polystyrene strip fixed to a sterile slide with the intima facing upwards. Glomeruli were isolated using a serial sieving technique (23) . In some experiments, tissues were lysed for SDS-PAGE analysis.
Fresh retina EC were isolated by hypotonic shock as described (24) . Briefly, the retina was placed in distilled water (1 h at 4°C) to permit osmotic lysis of the neural and glial elements, then transferred to a glass dish containing DNase I type II (Sigma, St. Louis, MO, USA) and gently sheared through a Pasteur pipette. The specimen was briefly digested using 0.5% collagenase type II (GIBCO BRL, Grand Island, NY, USA), 20 min, 37°C in DMEM. This procedure allowed the selective release of EC from the vascular network. The undigested clumps were separated by low-speed centrifugation. After several washes, the retinal EC were exposed to the peptide library. The purity of the EC preparation was assessed by immunostaining with a polyclonal anti-vWF antibody (Dako, Carpinteria, CA, USA).
Screening of the phage-display peptide library
A mix of three 8-mer libraries with distinct structure: linear [SX 8 (GS) 4 ], cyclic [SCX 8 C(GS) 4 ], and one which entails a linear structure followed by a cyclic portion [SX 4 CX 4 C(GS) 4 ], respectively; X represents any amino acid, S is invariant to ensure signal sequence cleavage and (GS) 4 is an 8 amino acid flexible spacer. The complexity of the library was ~5 x 10 8 , and its titer was ~10 13 PFU per ml (25) . The peptides were displayed fused to the pIII capsid protein of the filamentous phage M13. The initial input was ~3 x 10 11 PFU. Screening of the library on the intact aorta and isolated retinal EC was performed in DMEM (phenol-free)-Hepes (DH), pH 7.5, 0.5% nonfat dry milk, for 20 min at room temperature. After three washes with DH, bound phage was eluted with 50 mM (final) glycine, pH 2.0, 5 min, and neutralized with 100 mM (final) sodium phosphate, pH 7.4. An aliquot of the elution was used to titer phage recovery (25) . The remainder was amplified in DH5αF' (26) and used for the subsequent round of selection. The peptide-coding cDNA of relevant phage clones was sequenced as described before (26) . The sequences for phage clones used in this manuscript were the following: clone 45 (GGSGRLGW), clone 8 (YGAEVKRD), clone 23R (WMGARSIN), and clone 11 (SVPYPGFL).
Purification of rat profilin
Full-length rat profilin subcloned in pQE-30 (Qiagen, Valencia, CA, USA) downstream of a 6His-tag (kindly provided by M. Tamura) was expressed in M15 E. coli. Profilin was purified under native conditions by Ni ++ affinity chromatography using Ni-NTA agarose (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions.
Cell stimulation
Rat aortic EC were isolated as detailed in Doukas and Mordes (27) or were a gift from P. D'Amore laboratory. Briefly, the thoracic aorta was isolated, and the intercostal vessels and the distal end were clamped. 0.5% Collagenase (type I, Worthington Biochemical Corp., Freehold, NJ, USA) was injected from the proximal end and incubated at 37°C, 30 min. Cells were recovered and plated in low glucose DMEM/F12 (1:1) (GIBCO BRL, Grand Island, NY, USA) supplemented with 10% FBS (Gemini BioProducts, Woodland, CA), 12 µg/ml bovine brain extract (Clonetics, San Diego, CA), 50 µM hypoxantine, 2 mM L-glutamine, 100 µg/ml streptomycin, and 100 U/ml penicillin. Cultures between the fifth and thirteenth passage were used. In certain experiments, medium was added with D-glucose (final 30 mM) for different time periods. Free fatty acid stimulation was performed using equimolar concentrations of watersoluble linoleic acid and palmitic acid (dissolved in ethanol; both from Sigma, St. Louis, MO, USA) from 50 to 200 µM for one, four, and seven days. Concentrations above 200 mM were toxic. Stimulation with native or oxLDL (19.2 nmoles of MDA/mg protein; both from Biomedical Technologies, Inc., Stoughton, MA, USA) was performed for 24 h. Cholesterol, 7β-hydroxycholesterol, and 7-ketocholesterol (all from Sigma, St. Louis, MO, USA) were dissolved in ethanol and used at a final concentration of 0.4%. Stimulation with LDL and sterols was performed in cells cultured in lipoprotein-deficient serum.
Apoptosis
Cell death was evaluated by staining with Annexin V-EGFP and propidium iodide (to assess necrosis) under basal or hydrogen peroxide-stimulated conditions (0.25 mM for 16 h) according to manufacturer's protocol (Clontech, Palo Alto, CA, USA). At least 15,000 events were analyzed by flow cytometry.
Retroviral expression vectors and infection
The full-length rat profilin coding sequence (BamHI-HindIII) was digested from PR23-PROF (gift of M. Tamura) and cloned into BglII-HindIII sites of pLNCX2 (Clontech, Palo Alto, CA, USA). For siRNA experiments, an oligo corresponding to the 110-130 region of the profilin coding sequence (5′-GGAAGACCTTCGTTAGCATTA-3′) was devised and cloned as described previously (28) into ApaI-EcoRI sites of pLPU6, generated by replacing the CMV-MCS portion (NcoI-NotI) of pLPCX (Clontech, Palo Alto, CA, USA) with the BS/U6 MCS (gift of G. Sui). The PROF-pLNCX2 and PROF-pLPU6 constructs were transfected into 293GPG cells, the supernatant collected for 5 days, concentrated (25,000 x g, 90 min, 4°C) and used as described previously (29) . Cells were infected and selected with G418 (1 mg/ml) for pLPCX2 or puromycin (2 µg/ml) for pLPU6.
Northern blot
Total RNA was isolated, run under denaturing conditions, and blotted as described previously (30) . Full-length coding sequence of rat profilin and β-actin (Oncor, Gaithersburg, MD, USA) were labeled using Rediprime II (Amersham Biosciences, Piscataway, NJ, USA).
Filter retention assay and silver staining
150 µg EC lysates were obtained by scraping the aorta endothelium from control and diabetic rats (n =10), and were incubated with phage (5 x10 12 PFU), 90' 4C on a rotator. Mouse monoclonal antiphage M13 antibody (Amersham Biosciences, Piscataway, NJ, USA) (60 µg) was added, 20' at room temperature, and the mixture was spun through a 0.1 µm microporous filter (Millipore, Bedford, MA, USA), followed by extensive washing. The complex antibodyphage is efficiently retained on the 0.1µm filter (data not shown). The retentate was then diluted with urea (final conc. 3M) to elute the phage-associated proteins, and then centrifuged over a 100 kD cut-off filter (Amicon, Beverly, MA, USA). We chose the 100 kD filter because phage blots showed that the binding partner was ~15 kD. The sample was resolved by 15% SDS-PAGE under denaturing conditions and silver stained using a commercial kit (Silver Quest; Invitrogen, Carlsbad, CA, USA). Relevant bands were analyzed by microcapillary reverse-phase HPLC tandem mass spectrometry (µLC/MS/MS) on a Finnigan LCQ DECA quadrupole ion trap mass spectrometer (Harvard Microchemistry Facility, Boston, MA).
Western blot and immunoprecipitation
RAEC were harvested in radioimmunoprecipitation buffer (150 mM NaCl;10 mM NaPO 4 ; 2 mM EDTA; 1% NP-40; 1% deoxycolate; 0.1% SDS) to obtain total cell lysates. Differential detergent fractionation was performed as described previously (31) with a few modifications. Briefly, RAEC were grown on 15-cm dishes, placed on ice and the cytosolic/membrane fraction was extracted by gently shaking the cells for 30' with the following buffer: 10 mM PIPES, 100 mM NaCl, 5 mM EDTA, pH 6.8, 3 mM MgCl 2 , 300 mM sucrose, 0.01% digitonin, 0.5% Triton X-100 and protease inhibitors (2 mM PMSF, 2 mM Na 3 VO 4 , and aprotinin). The cytosolic extract was carefully collected, and the cytoskeletal fraction was obtained by scraping the remnant in 150 mM NaCl, 10 mM Na 2 PO 4 , 10 mM NaH 2 PO 4 , 2 mM EDTA, 0.1% SDS and protease inhibitors. With regard to the aorta, the endothelium was extracted by scraping the intima using EB (32) + 1.5% N-octylglucoside. Contamination from smooth-muscle cells was evaluated with SM-actin. Immunoprecipitation was performed using a rabbit polyclonal profilin antibody (1:100; kindly provided by M. Tamura), after preclearing the lysates with nonimmune rabbit IgG. Samples from cultured or aorta EC, and immunoprecipitates were analyzed by SDS-PAGE as described previously (32) . Immunoblot densitometric values were normalized for the respective loading control. Phospho-VASP was normalized for total VASP and RasGAP. With regard to phage interaction with recombinant profilin-1 or GST in vitro, clone 45 (10 11 PFU) or a nonspecific clone were incubated with the respective protein (10 nM), 1 h at 4C, then immunoprecipitated using a mouse monoclonal antiphage M13 antibody (1:300; Amersham Biosciences, Piscataway, NJ, USA) precoupled to Protein A-agarose. The following antibodies and concentrations were used for Western blot: profilin (1:2000); VASP (1:2000); Phospho-VASP (clone 16C2; 0.3 µg/ml; both from Calbiochem, San Diego, CA, USA); transferrin receptor (clone H68.4; 1 µg/ml; Zymed Laboratories, South San Francisco, CA, USA); SM-actin (clone 1A4; 1:3000; Dako, Carpinteria, CA, USA); rat ICAM-1 (1:1000; R&D, Minneapolis, MN, USA); caveolin-1 (1:5000; Santa Cruz Biotechnologies, Santa Cruz, CA, USA); Ras GAP (32); antiphage polyclonal (1:2000; Sigma, St. Louis, MO, USA); anti-GST mouse monoclonal (1:1000; Santa Cruz Biotechnologies, Santa Cruz, CA, USA).
Immunohistochemistry
Aortic rings from diabetic and control rats were embedded in OCT (Elkhart, IN, USA) and 8-µm frozen sections were stained with profilin (1:400), VASP (1:200) and Phospho-VASP (5 µg/ml) using the respective Cy3-conjugated rat-adsorbed secondary antibody (Jackson Immunoresearch, West Grove, PA, USA). For apoE null mice (14 weeks of age with or without 6 weeks of established diabetes), sections from the aortic sinus (33) were stained with profilin alone or in combination with PECAM-1 (clone 2H8; 10 µg/ml; Chemicon, Temecula, CA, USA) or F4/80 (clone A3-1; 10 µg/ml; Serotec, Raleigh, NC, USA). Nonimmune rabbit IgG or the respective isotype was used as a control in consecutive sections. For double labeling, we used biotinylated secondary antibodies followed by reaction with the respective peroxidase-or alkaline phospahatase-based ABC kit (Vector Laboratories, Burlingame, CA, USA) as described previously (30) .
With regard to phage staining, individual phage clones (n=123 for the aorta; n=33 for the retina) grown overnight in DH5αF' (GIBCO BRL, Grand Island, NY, USA) or, in other experiments, PEG-purified clones were incubated with sections. The average phage titer was 10 13 PFU/ml and 3 x 10 10 PFU/section were used (1:20 dilution in DH +2% nonfat milk). Sections were not permeabilized before adding the phage. The phage was detected with a monoclonal antiphage M13 antibody (Amersham Biosciences, Piscataway, NJ, USA) followed by an anti-mouse antibody conjugated to Cy3 (Jackson ImmunoResearch, West Grove, PA, USA). We screened retina clones fixing the sections before or after phage incubation. EC within the sections were identified using vWF (1:1000; Dako, Carpinteria, CA, USA) or PECAM-1 (see above). Images were captured and analyzed using IPLab software.
Statistical analysis
Data were expressed as mean ± SD of the difference vs. the control and analyzed using unpaired t-test. Flow cytometry data were expressed as percentage of positive cells.
RESULTS
Peptide library screening in diabetic aorta and retina
The first step of the experimental design was the screening of a high-complexity random peptide library (25) in the intact aorta and retinal EC isolated from 5-month diabetic rats within two hours of sacrifice (Fig. 1) . Retinal EC were obtained using a procedure based on the osmotic lysis of the neural and glial elements of the retina (24) . This technique minimizes the loss of cell surface domains as it does not involve tryptic digestion and yielded a relatively pure population of EC (>90%, as evaluated by vWF staining) (Fig. 1, inset) . After four rounds of selection, ~10 2 and 10 4 plaque-forming units (PFU) were rescued from the diabetic retina EC and the aorta, respectively. A randomly selected subset of phage clones was tested for their ability to bind the EC in tissue sections. To this end, 33 retina and 123 aorta phage clones were individually amplified, and used as a reagent to stain the respective tissue sections (n=6 per phage) obtained from diabetic and control rats. The results of the immunofluorescence analysis for the positive clones are indicated in Table 1 . The phage clones that were able to bind the retina and aorta sections (7/33 and 6/123, respectively) all stained selectively the EC, as evaluated by doublelabeling with the endothelial markers vonWillebrand Factor and PECAM-1 (data not shown). Approximately 50% of these phage clones were able to stain sections in a diabetes-specific manner. Phage clone 45 showed a unique patchy staining of the diabetic aorta EC, whereas the nondiabetic sections were negative (Table 1, inset). The positive phage clones were cross-tested on sections from other tissues. In line with the current notion of phenotypic heterogeneity of the endothelium (10, 11), we found that aorta phage clones would not stain retina sections and vice versa (data not shown). In addition, none of the aorta phage recognized kidney sections from either diabetic or age-matched nondiabetic rats (data not shown). Our results indicate that the surface of the diabetic EC in vivo displays a repertoire of disease-specific moieties that is, at least in part, regulated in an organ-specific manner.
Profilin-1 is a binding partner for clone 45
We reasoned that the identification of the binding partner(s) for the diabetes-specific clones could provide new insight into the molecular bases of EC dysfunction. The isolation/purification of the binding partner for phage clone 45 seemed potentially of interest because of the staining pattern obtained in immunofluorescence (Table 1 , inset). To gain information regarding the molecular weight of the putative binding partner(s), we set up a 'phage blot' method in which EC lysates obtained from the aorta of diabetic and control rats were analyzed by SDS-PAGE and probed with phage clone 45. A protein of the apparent molecular weight of 15 kD was recognized in the diabetic aorta by clone 45, but not clone 23R, here used as a control for nonspecific binding (data not shown). Thus, we attempted to purify the 15 kD protein from the aorta of ten diabetic or control rats (180 µg per group) by affinity chromatography using the synthetic peptide corresponding to the phage clone 45 sequence. This strategy repeatedly did not yield any candidate, possibly because the phage sequence surrounding the peptide contributed to the binding site of the peptide to its partners. Thus, we devised a filter retention assay which exploits the molecular mass of the phage particle (~16 MD) (Fig. 2a) . Aorta EC lysates from control and diabetic rats (n=10 per group) were incubated with phage clone 45, passed over a 0.1 µm microporous filter and, after several steps, the phage-associated proteins in the retentate were resolved by SDS-PAGE. Silver staining of the gel showed a ~15 kD band in the diabetic lysates incubated with clone 45, which was not detected in the control lysates or the diabetic lysates exposed to clone 23R (Fig. 2b) . We concluded that the 15 kD band was both clone 45-and diabetes-specific. Tandem-mass spectrometry analysis of the band yielded several matches for profilin-1 and hemoglobin. The latter is probably due to blood contamination of the lysates, whereas the finding of profilin-1 was unexpected. In fact, profilin-1 is best known as an intracellular protein and a major regulator of actin polymerization.
To validate profilin-1 as a binding partner for clone 45, we assessed their direct interaction in vitro. His-tagged recombinant profilin-1 (10 nM) and equimolar concentrations of purified glutathione S-transferase (GST) were incubated with clone 45 or the retina-specific clone 23R (10 11 PFU) and immunoprecipitated with a mouse monoclonal anti-phage antibody (Fig. 2c ). Under these conditions, profilin-1 coprecipitated with clone 45 but not with clone 23R. GST failed to coprecipitate with either phage. These data indicate a direct association between clone 45 and profilin in vitro; addition of 1 mM DTT to the reaction buffer did not affect their interaction (data not shown). For profilin to be a binding partner for clone 45, it must be located in the extracellular space, at least under certain conditions. Therefore, the surface expression of profilin was evaluated by flow-cytometry in profilin-1−overexpressing RAEC. We found that a small fraction of the cells expressed profilin on the surface, and that this fraction was increased in profilin-RAEC (11.8±2.9% vs. 6.2±2.3% in Vector-RAEC; n=3; P=0.01). Double-staining with propidium iodide and profilin showed that necrosis was not responsible for the highly positive population of cells.
In summary, we showed that profilin-1 was purified using the diabetes-specific phage clone 45 as an affinity matrix and, in turn, can interact with clone 45 in vitro.
Profilin-1 is increased in the diabetic aorta
Having isolated profilin-1 from the diabetic aorta, we began to address its role in diabetic EC dysfunction. When analyzed by Western blot, profilin levels were significantly increased in the aorta endothelium of 5-month diabetic rats (2.1±0.32-fold over control; n=5; P<0.05) and in human aorta specimens from diabetic donors (1.95±0.37-fold over nondiabetic specimens; n=3; P<0.05) (Fig. 3a) . Profilin levels were elevated also in diabetic glomeruli, but the difference did not achieve statistical significance.
Immunofluorescence analysis in rat aorta sections confirmed that profilin was increased in the diabetic specimens with a preferential staining of the endothelial layer (Fig. 3b) . These findings indicate that profilin is overexpressed in the aortic endothelium in response to the diabetic milieu.
Profilin-1 mediates endothelial dysfunction
To test the consequences of the profilin increase, we overexpressed the full-length protein in RAEC and sought for signs of EC dysfunction. First, we found that even modest increase in profilin accelerated apoptosis, evaluated by Annexin-V staining, when compared with empty vector-infected cells (12.5±3.3% vs. 5±2.1%; n=4; P<0.05) (Fig. 4a) . In contrast, no difference was observed in hydrogen peroxide-treated cells. Then, we assessed whether profilin overexpression could alter the levels of ICAM-1, a key player in leukocyte adhesion and inflammation. As shown in Fig. 4b , ICAM-1 was up-regulated in profilin-RAEC (2.2±0.14-fold over vector-RAEC; n=6; P=0.03). Likewise, ICAM-1 levels were significantly increased in the diabetic aorta EC in vivo (1.85±0.9-fold over control; n=8; P<0.05) (Fig. 4c) .
As a third measure of vascular dysfunction, we focused on VASP phosphorylation, an indicator of NO bioavailability (17, 18) . In profilin-RAEC, phospho-VASP was dramatically decreased (0.32±0.11-fold over vector-RAEC; n=4; P<0.01; Fig. 5a ), even though the total VASP levels were increased. Since profilin and VASP can interact (16), we examined whether the profilininduced decrease in phospho-VASP was due to VASP redistribution within the cell. In profilin-RAEC, VASP was partially relocated from the cytosolic to the cytoskeletal compartment in keeping with profilin partitioning. Moreover, the cytoskeletal VASP pool that coimmunoprecipitated with profilin showed significantly decreased phosphorylation (Fig. 5b) . Therefore, the profilin-induced redistribution of VASP may contribute to its decreased phosphorylation. We extended this in vitro finding to the study of VASP and phospho-VASP in the diabetic aorta in vivo. Phospho-VASP was significantly decreased in the diabetic aorta (0.52±0.13-fold over control; n=7; P<0.05) (Fig. 5c) , whereas VASP levels were comparable. Immunofluorescence analysis for phospho-VASP showed a marked decrease in the endothelial layer of the diabetic rat aorta. Conversely, staining for total VASP was similar in control and diabetic sections (Fig. 5d ). These results demonstrate a decreased activity of the NO-cGK pathway in situ.
In summary, the findings reported in Figs. 4 and 5 show that profilin-1 modulates at least three indicators of endothelial dysfunction: increased EC apoptosis, up-regulation of the adhesion molecule ICAM-1, and decreased VASP phosphorylation. The last two findings were recapitulated in the aorta of diabetic rats, suggesting a link between profilin increase and impairment of vascular function in vivo.
LDL/cholesterol, but not high glucose, can increase profilin-1 expression
To obtain further insight into the mechanisms elevating profilin-1 in diabetic vascular disease, we stimulated RAEC with LDL. Oxidized (Ox) and native LDL were able to up-regulate profilin-1 protein (Fig. 6a) and RNA levels (Fig. 6b) in a dose-dependent manner. Also, exposure to LDL decrease phospho-VASP, but in contrast to what observed in profilin-RAEC, this was not accompanied by an increase in total VASP levels (data not shown). We further investigated which component(s) of the oxLDL particle was sufficient to reproduce the profilin increase. Treatment with oxysterols (7-keto-and 7β-hydroxycholesterol), but not native cholesterol, was able to elevate profilin-1 (1.96±0.19-fold over control; n=6; P<0.001) (Fig. 6c) . 7-ketocholesterol also induced ICAM-1 expression concomitantly with profilin increase. Conversely, cells exposed to high (30mM) glucose, or increasing concentrations of free fatty acid (FFA), both hallmarks of type 2 diabetes, did not show any change in profilin levels (Fig.  6d) . Likewise, TNF-α, an inflammatory cytokine associated with the metabolic syndrome, or purified profilin did not up-regulate profilin (data not shown). These results suggest a critical regulatory function for LDL/cholesterol in the diabetes-mediated profilin increase.
Profilin-1 interference prevents LDL-stimulated ICAM -1 up-regulation
LDL, especially its oxidized form, triggers a cascade of events that may lead to EC dysfunction, including ICAM-1 up-regulation (34) . The parallel changes in profilin-1 and ICAM-1 levels both in vitro and in the diabetic aorta begged the question whether these two events were causally related. Using small interfering RNA(siRNA), we asked whether elevation of profilin-1 was required for the LDL-induced increase in ICAM-1. In oxLDL-treated RAEC, abrogation of profilin-1 de novo synthesis prevented the LDL-mediated ICAM-1 up-regulation (Fig. 7) . However, basal profilin levels were not decreased by siRNA, possibly as a consequence of the slow proliferation rate of RAEC following retroviral infection.
Profilin-1 is highly expressed in atherosclerotic lesions
Since atherosclerosis is heralded by loss of endothelial function and is a prevalent complication of both type 1 and type 2 diabetes, we studied profilin-1 expression in the atherosclerotic plaque. To this end, we stained sections cut from the aortic sinus of apoE null mice with or without 6 weeks of established diabetes (n=6 per group). The apoE null mouse is a validated model of atherosclerosis and displays elevated levels of VLDL and LDL (35) that are further enhanced by diabetes (33) . Profilin expression was dramatically up-regulated in atherosclerotic lesions when compared with the adjacent lesion-free, Oil Red O-negative areas (Fig. 8a) . Double-labeling with the endothelial marker PECAM-1 revealed that profilin was highly expressed in EC within the plaque (Fig. 8b) . Also, macrophages, identified by F4/80 staining, were often positive for profilin (Fig. 8c) . As shown before, diabetic mice displayed a significant increase in atherosclerotic lesion area (33) . The elevated expression of profilin-1 in EC and macrophage within the plaque was observed in both diabetic and normoglycemic apoE null mice with a moderate increase in the intensity of the staining in diabetic specimens (data not shown). These results suggest a role for profilin-1 in atherosclerosis and are consistent with the finding of LDL as a mediator of profilin increase.
DISCUSSION
Although it is generally accepted that the diabetic milieu affects the membrane of EC, the underlying molecular changes are poorly understood in vivo. In this study, we have used a comprehensive and unbiased approach to 1) address changes occurring on the surface of diabetic EC, 2) isolate/purify the respective proteins and 3) begin to test their role in diabetic endothelial dysfunction. The identification of peptides specific for the endothelium of diabetic retina and aorta proves our working hypothesis that diabetes changes the surface of the endothelium and adds the diabetic vascular disease to the growing list of successful application of phage-display library. We extended the identification of diabetes-specific peptides by isolating their binding partners on the endothelium. The finding of profilin-1 as a binding partner for a diabetic aorta clone was initially surprising. In fact, profilin-1 is best known to reside inside the cell where it promotes actin-polymerization (13, 14) , binds to signaling molecules such as PtdIns-4,5-P 2 (PIP 2 ) (36), and is recruited within functional modules regulating endocytosis (37) and phagocytosis (38) . Its expression increases in EC treated with homocysteine under laminar flow conditions (20) , and in an experimental model of glomerulonephritis it is released in the extracellular mesangial space (21) . Notably, profilin-1 does not contain a signal peptide, but it can be secreted via small vesicles called exosomes (39) . Our data support a redistribution of profilin-1 in the extracellular space when overexpressed in cells and possibly in the diabetic aorta. The elevation of extracellular profilin-1 begs the question whether this pool is responsible for at least some of the changes observed in profilin-overexpressing cells or is a mere consequence of total profilin increase. Preliminary results with EC exposed to recombinant profilin-1 show that extracellular profilin was not able to up-regulate ICAM-1 or elicit changes in VASP phosphorylation (unpublished observations). Further studies are necessary to characterize the function of the extracellular protein.
Importantly, we have begun to test the role of profilin in diabetic EC dysfunction. We demonstrated that profilin-1 levels are increased in the aorta endothelium of both human and experimental diabetes. Profilin overexpression in primary aorta EC was able to trigger a maladaptive program characterized by increased apoptosis, ICAM-1 up-regulation, and decreased VASP phosphorylation. The last two alterations were recapitulated in the diabetic aorta in vivo. Also, we found that LDL/cholesterol signaling, but not high glucose, regulates profilin which, in turn, was required for LDL-mediated ICAM-1 up-regulation. Finally, profilin was markedly increased in EC and macrophages within atherosclerotic lesions of apoE null mice.
Decreased levels of Phospho-VASP in the diabetic aorta represent direct evidence of a defect in the NO-cGK pathway. This result is in line with reports of impaired endothelium-dependent vasodilation in type 1 (40) , and type 2 (41) diabetic patients. Also, the finding that profilin-1 upregulation can alter VASP distribution and concomitantly its phosphorylation suggests a spatially regulated scheme of activation for VASP. For instance, VASP partitioning to actin-rich docking structures is critical for ICAM-1-mediated leukocyte adhesion to the endothelium (42) . ICAM-1 was another indicator of endothelial injury modulated by profilin-1. In correlative studies, soluble levels of ICAM-1 were increased in type 2 diabetic patients (43), associated with early signs of atherosclerosis (44) , and predicted coronary artery disease (45) . Our study is the first quantitative evidence of an in situ increase in ICAM-1 in the diabetic aorta and supports the hypothesis of an inflammatory/reactive phenotype of the diabetic endothelium (46, 47) . Finally, the coexistence of decreased Phospho-VASP and ICAM-1 up-regulation in association with profilin increase suggest an interplay among these events in vascular dysfunction, both in vitro and in vivo. The above findings were obtained upon a moderate profilin overexpression. Notably, the changes induced by profilin overexpression may extend beyond those observed in our system; for instance, Moldovan et al. have found that, when dramatically overexpressed, profilin regulates EC adhesion to fibronectin by increasing the recruitment of fibronectin receptors to the plasma membrane (15) .
We have also begun addressing the mechanisms operating in diabetes-mediated profilin overexpression. OxLDL/oxysterols was able to trigger profilin increase, consistently with the profilin staining in lipid-laden cells within the plaque. Conversely, high glucose was not sufficient to elicit profilin-1 protein in aortic EC. Of note, Clarkson et al. reported that profilin-1 mRNA was elevated in mesangial cells exposed to high glucose and in the diabetic rat kidney (19) . The inability of high glucose per se to increase profilin-1 protein levels in EC is in keeping with a multifactorial pathogenesis of endothelial dysfunction associated with the metabolic syndrome and may reflect the limited effect of glucose-lowering monotherapy in preventing macrovascular complications in type 2 diabetic patients (6) . The increase in profilin-1 following exposure to oxysterols could be, at least in part, modulated by the inhibition of the sterolregulated transcription factors SREBPs (unpublished observations), whose activation is abrogated by sterol loading (48) . Thus, we propose a new model whereby profilin-1 contributes to diabetic macrovascular disease as an effector of a metabolic pathway downstream of oxLDL/oxysterols. In addition, they underscore the utility of this approach for the unbiased discovery of cell surface targets in the diabetic endothelium. Results of phage binding to retinal sections obtained from nondiabetic and diabetic rats. For each of the phages, at least 4 independent sections were tested. A total of 33 random phage clones from round 4 were screened, and 7 were positive (21%). With the exception of clone 4, staining of the retina clones was abrogated by fixation. As a first step, a peptide phage-display library was screened on freshly isolated retina EC or the intact aorta of diabetic rats (1) . The purity of the retina EC preparation was tested by vWF staining (inset). After appropriate selection, a subset of phage clones was tested for their ability to recognize the EC in tissue sections (2) . Then, the binding partner (i.e., profilin-1) for one of the diabetic-specific clones was purified (3) and its direct interaction with the cognate clone was confirmed using a biochemical assay (4) . Finally, the role of profilin-1 in diabetic vascular disease was evaluated using both in vitro and in vivo models (5). EC and glomeruli from control (C) and diabetic (DM) rats (n = 5 per group) and human aorta (n = 3). Profilin-1 levels were significantly increased in rat and human DM aorta (bar graph represents the data on rat; *P < 0.05). Profilin-1 levels were normalized for transferrin receptor levels, here used as a loading control. Smooth muscle (SM)−actin was used to assess the contamination from smooth muscle cells; positivity in the glomeruli is attributable to mesangial cells. The relative molecular weight (kD) of the proteins is indicated on the left. b) Immunofluorescence analysis of profilin in rat aorta sections shows a significant increase in the diabetic aorta, mainly at the level of the endothelium (EC). Sections were counterstained with DAPI. Adv.: Tunica Adventitia. Scale bar: 12 µm. Phospho-VASP was significantly decreased in cells overexpressing profilin-1 despite an increase in total VASP. b) In profilin-RAEC, VASP is redistributed in the cytoskeletal fraction in keeping with profilin partitioning (upper blots). Also, the VASP pool associated with profilin in the cytoskeleton displays a decreased phosphorylation (lower blots). c) Immunoblot analysis for VASP in rat aorta. Phospho-VASP levels are significantly decreased in the diabetic (DM) aorta when compared with control (C) (n=7; *P<0.05). Data are normalized for total VASP and RasGAP levels, as a control for loading. The relative molecular weight (kD) of the proteins is indicated on the left. d) Immunofluorescence analysis for VASP confirms a significant decrease for Phospho-VASP (upper panels) in the diabetic endothelium (EC), whereas the staining for total VASP (lower panels) is comparable in control and diabetic sections. Adv.: Tunica Adventitia. Scale Bar: 50 µm. RNA was isolated and subjected to Northern blotting with the indicated probes. c) Immunoblot analysis shows that oxysterols (7β-hydroxy-and 7-ketocholesterol), but not cholesterol, can elevate profilin-1 levels (n=6; P<0.001). Treatment with 7-ketocholesterol determined a parallel increase in ICAM-1. Caveolin-1, known to be regulated by sterols, was used as positive control. d) In contrast, RAEC exposed to high glucose (HG; 30mM) for two weeks or to increasing concentrations of free fatty acids (FFA) did not show any profilin-1 elevation. The relative molecular weight (kD) of the proteins is indicated on the left. 
